Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gallant Therapeutics
San Diego, California, USAgallant.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Gallant Therapeutics develops off-the-shelf mesenchymal stem cell therapies targeting the root causes of major diseases in dogs and cats. The company’s lead candidate—an allogeneic uterine-derived MSC product for feline chronic gingivostomatitis—is currently undergoing a pivotal study with anticipated conditional FDA approval by 2025. Early pilot studies have shown positive results across several indications including osteoarthritis and CKD. The company has raised over $26 million to date, including a recent $15 million Series A round.
- Therapeutic areas
- RheumatologyImmunologyNephrology
- Modalities
- Mesenchymal stem cells (MSCs)cell therapyregenerative medicine
- Industry
- Veterinary
02
Partnerships
Investors include BOLD Capital Partners and Digitalis Ventures; no major pharma partnerships disclosed yet but investor support noted.
Beyond the preview
Go deeper on Gallant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gallant Therapeutics.